The effect of long-term treatment with sodium nedocromil on airway hypereactivity was investigated in two groups of 20 patients each. Group I patients presented with allergic asthma while Group II patients presented with intrinsic asthma. For each subject of the two groups, the base FEVI was measured and nebulized methacholine was administrated in consecutively higher concentrations until a decrease in FEVI of >20 % was observed. Following measurement, all patients included in the study were treated with 12 mg of sodium nedocromil per day for 12 months. At the end of the treatment, bronchial hyperreactivity was evaluated for a second time by administering the same dosage of methacholine that originally produced a decline in FEVI of>20%. In Group I patients (allergic asthma) mean FEVI was 3126 ml, before challenge, while after methacholine challenge FEVI was 2400ml. Following I-year of sodium nedocromil administration the FEVI was 2601ml (p<0.05). Before treatment, the mean fall in FEVl, following methacholine challenge, was 23.67 % while following a l-year-Iong sodium nedocromil administration this value reduced to 15.7(!% (p<0.05). Correspondingly, PC zo was 5.59 while after sodium nedocromil administration it increased to 11.66 (p<0.05). In Group II patients (intrinsic asthma) mean FEVI was 2750 ml, before challenge, while after methacholine challenge FEVI was 2066ml. Following I-year of sodium nedocromil administration the FEVI was 2223ml (p<0.05). Before treatment, the mean fall in FEVl, following methacholine challenge, was 27.65% while following a l-year-Iong sodium nedocromil administration this value reduced to 21.92% (p<0.05). Correspondingly, PC zo was 5.91 while after sodium nedocromil administration it increased to 6.19 (p<0.05). The results suggest a positive effect of long-term sodium nedocromil administration in bronchial hyperreactivity for both groups of patients.
The main characteristics of bronchial asthma are bronchial hyperreactivity and airway inflammation. Bronchial hyperreactivity is expressed by an increased airway reactivity to various factors such as different allergens, viral infection, cold temperatures and environmental or work-related factors (1) (2) (3) (4) . Inflammation of the airways is the most important of the pathophysiological manifestations of bronchial asthma and the main reason for the presence of bronchial hyperreactivity (5) (6) .
The inflammation process evolves in three reaction phases: (a) the acute phase which is clinically expressed by bronchial spasm, (b) the delayed phase which presents with a persistent clinical expression and its pathology is characterized by bronchial edema and (c) the subacute or chronic phase when the bronchi are typically invaded by inflammation cells. The clinical manifestation of asthma depends on the interaction of a host of triggering factors and the concomitant release of inflammation mediators from various other factors that take part in the vicious circle of asthma related events (7) . Bronchial hyperreactivity is often found in healthy individuals, especially those with a family history of atopic disease, in patients suffering from allergic rhinitis, in smokers, in chronic obstructive pulmonary disease (COPD), in cystic fibrosis and in bronchiectasis. It is estimated that the incidence ofhyperreactivity in bronchial asthma is higher than 80% (8-10) while the course of asymptomatic bronchial hyperreactivity in asthma sufferers may be related to age. Its presence, in childhood and pre-puberty, does not imply a risk factor for the manifestation of asthma (11) .
The purpose of the present study is to explore the effects of long-term sodium nedocromil administration on bronchial hyperreactivity.
MATERIALS AND METHODS
A total of forty subjects participated in the study (twenty-one female and nineteen male). Twenty patients (12 women and 8 men, mean age 31.6 years) presented with allergic asthma (Group I). A second group (Group II) of another twenty patients (9 women and I I men, mean age 48,8 years) presented with intrinsic asthma. Allergic asthma was identified by dermatological sensitivity tests (prick tests) that showed 12 subjects with an allergy to mites (7 to D. pteronyssinus alone and 5 to both D. pteronyssinus and D. farinae). Eight subjects were allergic to pollen, 5 to mixed grasses and 3 to mixed corn pollen. All of the subjects were asymptomatic during the study and none was under any systematic medication.
Once admitted to the study, the baseline value of FEV 1(Forced Expiratory Volume in 1s) was determined for each subject using the Spirolite 101 spirometer. Having determined the base value of FEV1,the evaluation of bronchial hyperreactivity followed, using a dilution of methacholine delivered from the Pari provocation test nebulizer. Beginning with a concentration of 0.125mg/ml, which was the starting-point for the methacholineprovocation used in this study, the challenge was repeated, each time doubling the dose of methacholine, until the highest acceptable level of 16mg/ml was reached. For each subject, the threshold of hyperreactivity was identified as a specific dose of methacholine. For each threshold determination, the provocation was continued until a drop in FEV 1 >20 % (PC zo )' was observed (11) (12) .
Following determination of the baseline value of FEV 1 and bronchial hyperreactivity threshold, every patient of both groups were treated by administering 12mg of sodium nedocromil per day for one year. At the end of the treatment period, bronchial hyperreactivity was estimated using the same dosage of methacholine that produced the decline in FEV1>20% before treatment started. Statistical analysis ofthe results was performed by paired t-test, Two statistical estimations were made; one for the comparison of FEV I deviations without medication and another for the comparison of FEV 1 deviations after a year of administrating sodium nedocromil. (Tab. III).
RESULTS
The results of the study are represented in the series of Tables I, II and III. From these tables it becomes evident that both patient groups showed an increased bronchial hyperreactivity at the relatively low methacholine concentrations of 5.7mg/ml, for Group I with allergic asthma, and 5 .6mg/ml for Group II with intrinsic asthma. After the continuous administration of sodium nedocromil for twelve months the subjects of both groups showed a decrease of bronchial hyperreactivity.
For the subjects of Group I, the percentage (%) of change in FEYI values were reduced from 23.67% to 15.70% (p<0.05). PC 20 increased from 5.59 to 11.66, p<0.05 (Tab. I).
For subjects of Group II, the percentage (%) ofchange in FEY 1 values was reduced from 27.65% to 21.92% (p<0.05). PC 20 was increased from 5.91 to 6.19, p<0.05 (Tab. I)
There was a greater reduction ofhyperreactivity in patients with allergic asthma.
DISCUSSION
It is well documented, and widely accepted, that corticoids and non-steroidal antinflammatory substances (NSAIDS), such as sodium chromoglyconate or sodium nedocromil, decrease bronchial hyperreactivity in patients after both long-and short term therapies (13-17). Their beneficial effect of reducing bronchial hyperreactivity, which decreases both the frequency and the severity of the asthmatic attacks, results in a clear improvement in the clinical picture (18) (19) . Particularly significant is the resulting decrease in the frequency and dosage of oral or injectable corticosteroids.
The main focus of the present study was the evaluation of administration of sodium nedocromil to two groups of patients, one with allergic and one with intrinsic asthma. These two entities present both similarities and differences, both in their pathology and in their pathophysiology, incl uding the mechanisms by which anti-inflammatory substances produce a decrease of hyperreactivity in each case.
The action of steroids and NSAIDS, such as sodium nedocromil, focuses mainly on the inflammatory cells tha t are stimulated by specific and non-specific factors (18, 19) . As far as the mechanism of corticosteroid action is concerned, the focu s is on reducing the synthesis and the release of mediators from the mast cells, eosinophils, basophils, neutrophils, monocytes, macrophages and lymphocytes, on protecting the bronchial mucous membrane, on reducing secretion from mucosal glands, on limiting edema and on restricting capillary permeability ( 14, 15, 16, 20) . As for the action of sodium nedocromil , the focus is on the inflammatory cells that are stimulated by specific and non-specific factors (21) . Furthermore, it has been shown that sodium nedocromil inhi bits the axonal reflex by blocking the release of neuropeptides (22) .
The results suggest a positive effect with the employment of long-term sodium nedocromil administration in terms of the observed reduction in bronchial hyperreactivity in subjects with either allergic or intrinsic asthma, with a greater effect observed in the former group. This reduction was clearly evident by the relatively small drop of FEY 1 and the substantial rise ofPC 2o ' For subjects of Group I the percentage (%) of change in FEY 1
Tab. I. Initial (basic) rates and rates after bronchial challenge, spirometric index before and after treatment. Group I: Group of patients with allergic asthma. Group I: Group of patients with allergic asthma followin g 12 months of therapeutic treatment with sodium nedocromil. Group II: Group of patients with intrinsic asthma. Group II: Group of patients with intrinsic asthma fo llowing 12 months of therapeutic treatment with sodium nedocromil. Indeed, inh alant anti-inflammatory drug s play a major role in the man agement of asthma; they ameliorate the clinical manifestation s of the disease, they redu ce the frequency of asthmatic attac ks and they improve the quality ofl ife for asthma patient s. They also provid e a long-term prospect forreducing bronchial hyperreacti vity and inflammation , potentially lead ing to a complete control of the disease.
